OMERS ADMINISTRATION Corp Boosts Stake in United Therapeutics Corporation $UTHR

OMERS ADMINISTRATION Corp increased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 83.8% during the first quarter, Holdings Channel.com reports. The firm owned 12,641 shares of the biotechnology company’s stock after purchasing an additional 5,764 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in United Therapeutics were worth $7,496,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Arjuna Capital grew its holdings in United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after purchasing an additional 18 shares during the period. Sage Rhino Capital LLC increased its position in United Therapeutics by 5.1% in the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after buying an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC raised its stake in shares of United Therapeutics by 5.4% in the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after buying an additional 24 shares during the period. Meeder Advisory Services Inc. lifted its holdings in United Therapeutics by 4.1% during the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 26 shares in the last quarter. Finally, Independent Advisor Alliance lifted its holdings in United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 27 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

United Therapeutics stock opened at $528.47 on Monday. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The firm’s 50 day moving average price is $547.88 and its 200-day moving average price is $531.69. The stock has a market cap of $22.43 billion, a P/E ratio of 19.51, a PEG ratio of 1.77 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s revenue was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.63 EPS. As a group, equities analysts expect that United Therapeutics Corporation will post 26.65 EPS for the current year.

Insiders Place Their Bets

In other news, Director Jan Malcolm sold 325 shares of United Therapeutics stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $550.59, for a total value of $178,941.75. Following the sale, the director directly owned 450 shares of the company’s stock, valued at approximately $247,765.50. The trade was a 41.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $535.99, for a total value of $5,091,905.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at $21,714,562.87. This trade represents a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 493,833 shares of company stock worth $275,841,047 in the last 90 days. 8.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of analyst reports. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research note on Thursday, May 7th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Raymond James Financial initiated coverage on shares of United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Royal Bank Of Canada increased their price target on United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Finally, Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $648.33.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.